Experience

Ongoing Projects

CAPACITY BUILDING

 

HATCap: Trial capacity platform for Human African Trypanosomiasis (HAT, sleeping sickness) in Africa


Role of MedRes: Contribution to clinical trial methodology development, laboratory improvement, strengthening & harmonisation of regulatory practices throughout the region affected by HAT
Countries: Angola, Central Africa Republic, Dem. Rep. of the Congo, Rep. of Congo, South Sudan, Uganda
Source of monetary support: Drugs for Neglected Diseases Initiative

Research Trials

MATIAS: Observational Study to Support artesunate introduction in the Democratic Republic of the Congo (DRC)
Non-controlled longitudinal implementation study; 700 patients

Role of MedRes: project management and implementation
Countries: Democratic Republic of the Congo
Sponsor: Swiss TPH (funding Medicines for Malaria Venture)

INVESTIGATOR DRIVEN CLINICAL TRIALS
---

SHORT TERM CONSULTANCIES
---

Past Experience

CAPACITY BUILDING

 

ARCEAU-RDC : Alliance for Clinical Research and Clinical Epidemiology in the DRC / Alliance pour la recherche clinique & épidémiologie clinique- expansion and promotion of clinical research capacities in collaboration with two partner organizations in Kinshasa, Dem. Rep. of the Congo (Kinshasa School of Public Health & Biamba Marie Mutombo Hospital).
Role of MedRes: The activities include the construction / renovation of laboratories, creation of quality assurance system, staff training (see: www.arceau-rdc.org)
Countries: Democratic Republic of the Congo
Source of monetary support: Bill & Melinda Gates Foundation

 

Reference center for human African trypanosomiasis (HAT), BCT Democratic Republic of the Congo:
Development of a reference structure (laboratories, clinic) for the diagnosis and treatment of HAT (sleeping sickness)
Role of MedRes: Conceptional work, fundraising, procurement, implementation
Country: Democratic Republic of the Congo
Source of monetary support: Swiss Agency for Development & Cooperation (SDC), Bureau Central de la Trypanosomiase (BCT) Democratic Republic of the Congo

 

Reference center for human African trypanosomiasis (HAT), ICCT Angola:

Development of a reference structure (laboratories, clinic) for the diagnosis and treatment of HAT (sleeping sickness)
Role of MedRes: Conceptional work, fundraising, procurement, implementation
Country: Angola
Source of monetary support: Swiss Agency for Development & Cooperation (SDC), Norwegian Peoples Aid, Ministry of Foreign Affairs, France

INVESTIGATOR DRIVEN CLINICAL TRIALS


IMPAMEL III : Abbreviated melarsoprol regimen for second stage Human African Trypanosomiasis (sleeping sickness) T.b. rhodesiense form, Phase II - Proof of concept & drug utilization trials, total 120 patients
Countries: Uganda, Tanzania
Source of monetary support: Swiss Agency for Development & Cooperation (SDC), Swiss Tropical & Public Health Institute
Sponsor: Swiss Tropical & Public Health Institute

 

IMPAMEL II: Abbreviated melarsoprol regimen for second stage Human African Trypanosomiasis (sleeping sickness), Phase IIIb effectiveness study, 2’500 patients
Countries: Ivory Coast, Democratic Republic of the Congo, Angola, Uganda, South Sudan, Central African Republic, Equatorial Guinea, Republic of Congo
Source of monetary support: Swiss Agency for Development & Cooperation (SDC)
Sponsor: Swiss Tropical & Public Health Institute

 

IMPAMEL I: Abbreviated melarsoprol regimen for second stage Human African Trypanosomiasis (sleeping sickness), Phase III, 500 patients
Country: Angola
Source of monetary support: Swiss Agency for Development & Cooperation (SDC)
Sponsor: Swiss Tropical & Public Health Institute

SHORT TERM CONSULTANCIES


Project Review: Mid-term project review in several public health institutions in the Democratic Republic of Congo (DRC) (Directorate General for Development Cooperation, Belgium)
Role of MedRes: Conduct of review
Country: Dem. Rep. of the Congo
Mandator: Directorate General for Development Cooperation, Belgium – through Swiss Centre for International Health

 

Scientific support: Upgrade of Coartem® to first line treatment against non-complicated malaria – facilitation of discussions with Ministry of Health
Country: Democratic Republic of the Congo
Mandator: Novartis Pharma

For further information of MedRes experience see also:

 

Pharmaceutical Medicine Unit


Quality Management Services